S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway
Xianwei Zhou(Nanjing Drum Tower Hospital), Binghua Li(Nanjing Drum Tower Hospital)
Cited by 3
Related Papers
Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
|Scientific Reports|2017|83
Long noncoding RNA BSN-AS2 induced by E2F1 promotes spinal osteosarcoma progression by targeting miR-654-3p/SYTL2 axis
|Cancer Cell International|2020|18